Shree Ganesh Biotech India Ltd (SHREEGANES) — shareholding pattern, promoter holding, financials and share price
About Shree Ganesh Biotech India Ltd (SHREEGANES)
Shree Ganesh Biotech India Ltd operates in the Biotechnology industry, within the Healthcare sector. It trades on the NSE as SHREEGANES and on the BSE under scrip code 539470. Its ISIN is INE051N01026.
Incorporated in 1982, Shree Ganesh Biotech Ltd is engaged in the trading of seeds and bhushi. [1]
Shree Ganesh Biotech India Limited specializes in the production, processing, and marketing of high-quality hybrid seeds for various crops including corn, sunflower, cotton, paddy, and grain sorghum.
Originally established as a commercial and investment entity in 1982, the company underwent a significant transformation in 2010 with the merger of Shree Ganesh Bio-Tech (India) Private Limited, shifting its focus to the biotech sector.
Listed peers in Biotechnology: Venmax Drugs & Pharmaceuticals Ltd, Ishita Drugs & Industries Ltd, Cian Healthcare Ltd, Centuple Global Ltd, Rekvina Labs Ltd, Mono Pharmacare Ltd.
Valuation & Returns
10 Jul 2026At ₹0.54 a share on 10 Jul 2026, Shree Ganesh Biotech India Ltd (SHREEGANES) was valued at a price-to-earnings ratio of 42.21x against an industry P/E of 36.41x and a price-to-book of 0.34x on a book value of ₹1.59 per share as of Mar 2025. Solomo computes return on equity of 0.81% and return on capital employed of 0.81% from filed results. Earnings ratios use standalone results for the twelve months Jun 2025 to Mar 2026.
- P/E
- 42.21x
- Industry P/E
- 36.41x
- P/B
- 0.34x
- EPS (TTM)
- ₹0.01
- Book value / share
- ₹1.59
- ROE
- 0.81%
- ROCE
- 0.81%
- ROA
- 0.8%
- Debt / equity
- 0x
- Dividend yield
- 0%
- EBITDA margin
- 10.26%
- 52-week range
- ₹0.52 – ₹0.85
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Shree Ganesh Biotech India Ltd (SHREEGANES) reported revenue of ₹4.97 crore, net profit of ₹0.38 crore and earnings per share of ₹0.01. That compares with revenue of ₹22.96 crore and net profit of ₹0.28 crore in Mar 2025. Figures are standalone, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹2.12 crore and net profit ₹-0.15 crore (standalone).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 72.64 | 62.45 | 20.28 | 22.96 | 4.97 |
| Net profit (₹ cr) | 2.53 | 2.04 | 0.62 | 0.28 | 0.38 |
| EPS (₹) | 0.06 | 0.05 | 0.02 | 0.01 | 0.01 |
| Measure | 10Y | 5Y | 3Y | 1Y |
|---|---|---|---|---|
| Sales growth | 30.31% | 56.15% | -31.89% | 13.21% |
| Profit growth | -7.08% | 3.37% | -52.05% | -54.84% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 0% of Shree Ganesh Biotech India Ltd (SHREEGANES) (unchanged from the previous quarter), foreign institutional investors (FII) hold 1.42%. Market capitalisation was ₹22 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Sep 2015.
Largest disclosed public shareholders in Jun 2026: NEW ERA FUND LIMITED 1.42%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 0% | - | 1.42% | - | 100% |
| Mar 2026 | 0% | - | 1.42% | - | 100% |
| Dec 2025 | 0% | - | 1.42% | - | 100% |
| Sep 2025 | 0% | - | 1.42% | - | 100% |
| Jun 2025 | 0% | - | 1.42% | - | 100% |
| Mar 2025 | 0% | - | 1.42% | - | 100% |
| Dec 2024 | 0% | - | 1.42% | - | 100% |
| Sep 2024 | 0% | - | 1.42% | - | 100% |